It also suggests that in our study population, the pathway linking atherogenic dyslipidemia per se to carotid plaque may be less prominent than the pathway involving insulin resistance and glucose homeostasis, which is uniquely disrupted by the MASLD milieu. The gene discussed is INS; the disease is metabolic syndrome.